The global graft versus host disease market size was US$ 3.0 billion in 2021. The global graft versus host disease market size is estimated to reach US$ 9.3 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.5% during the forecast period from 2022 to 2030.
Graft-versus-host disease (GVHD) is a systemic ailment that occurs when the immune cells of the graft identify the host as an alien and attack the cells of the recipient's body. 'Graft' refers to the donated or transplanted tissue, and 'host' refers to the recipient's tissue. It is a common intricacy behind the allogeneic hematopoietic stem cell transplant (HCT).
Factors Affecting Market Growth
The increase in the geriatric population and rise in the majority of myeloma, leukemia, nephrological, and lymphoma cancer is anticipated to drive the global market.
The rising number of bone marrow transplants around the globe to manage specific cancer types boost the global market.
Improvements in the diagnostic standards of the disease, authorization of novel therapies, and a vast spectrum of prophylaxis possibilities are expected to drive the global market.
Lack of awareness and the high cost of the chemotherapeutic treatment of the disease is anticipated to hinder the growth of the global market.
Impact Analysis of COVID-19
COVID-19 negatively impacted the global market due to a decrease in the number of transplantation procedures. The reusable tools that are regularly used in transplant procedures with close contact with patients increase the risk of spreading the disease. Also, the pandemic has greatly affected solid organ transplants (SOTs). At an early stage, transplant committees suggested the suspension of living kidney transplant schedules in communities with the overall transmission, to save recipients from high risk of immunosuppression, it is advised to reserve while allowing deceased-donor kidney transplants for life-saving gestures.
The North American market was leading in terms of revenue in 2021 because of the growth in allogeneic transplant procedures, the increased number of organ donations from departed persons for transplantation, and an increase in the number of cancer patients.
The prominent players in the global graft-versus-host disease market are:
Asahi Kasei Corporation
Bristol Myer Squibb
Accord Healthcare Limited
Merck & Co
The global graft-versus-host disease market focuses on Product Type, Treatment Type, End Use, and Region.
Segmentation on the basis of Product Type
Segmentation on the basis of Treatment Type
Segmentation on the basis of End Use
Segmentation on the basis of Region
Rest of Western Europe
Rest of Eastern Europe
Australia & New Zealand
Rest of Asia Pacific
Middle East & Africa (MEA)
Rest of MEA
Rest of South America